1 / 76

Infection Control in Dialysis Unit Hemodialysis Symposium

Infection Control in Dialysis Unit Hemodialysis Symposium. Dr. Shoeb Mohammed, M.D. Diplomate of American Boards in Nephrology and Internal Medicine Consultant Nephrologist, King Fahd Hospital, Madina. Objectives.

galvin
Download Presentation

Infection Control in Dialysis Unit Hemodialysis Symposium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infection Control in Dialysis UnitHemodialysis Symposium Dr. Shoeb Mohammed, M.D. Diplomate of American Boards in Nephrology and Internal Medicine Consultant Nephrologist, King Fahd Hospital, Madina

  2. Objectives • Review latest infection related mortality and hospitalization data among dialysis patients from USRDS 2013. • Review blood stream infections in HD. • Learn about the CDC Collaborative for control of blood stream infections in dialysis. • Control of HBV/HCV/HIV and pulmonary infections. • Vaccinations in dialysis

  3. ESRD: Chapter Five Mortality United States Renal Data System 2013 Annual Data Report

  4. Incident & prevalent patient counts (USRDS), by modalityFigure 1.1 (Volume 2) Incident & December 31 point prevalent ESRD patients; peritoneal dialysis consists of CAPD & CCPD.

  5. Adjusted all-cause mortality rates (from day 1 and day 90), by modality & year of treatmentFigure 5.1 (continued; Volume 2) Incident ESRD patients. Adj: age/gender/race/primary diagnosis; ref: incident ESRD patients, 2010.

  6. ESRD: Chapter Three Hospitalization United States Renal Data System 2013 Annual Data Report

  7. Change in adjusted all-cause & cause-specific hospitalization rates, by modalityFigure 3.1 (Volume 2) Period prevalent ESRD patients. Adj: age/gender/race/primary diagnosis; ref: ESRD patients, 2010.

  8. Adjusted cause-specific hospitalization rates, hemodialysisFigure 3.1 (Volume 2)

  9. Adjusted rates of hospital admissions, by modality & diagnosis code type: Bacteremia/SepsisFigure 3.5 (Volume 2) Period prevalent ESRD patients. Adj: age/gender/race/primary diagnosis; ref: ESRD patients, 2010.

  10. Rehospitalization or death within 30 days after live hospital discharge, by cause-specific index hospitalization, 2011Figure 3.16 (Volume 2) Period prevalent hemodialysis patients, all ages, 2011; unadjusted. Includes live hospital discharges from January 1 to December 1, 2011.

  11. In Summary • Blood stream infections (BSIs) remain a major cause of morbidity and mortality in hemodialysis pts. • The rate of hospitalizations for bacteremia / sepsis has increased by 42.9 % since 1995. (USRDS 2013) • More than 37000 access related BSI admissions in 2008 in USA due to dialysis catheters. (MMWR, 2011) • BSIs lead to severe complications of endocarditis, septic emboli, metastatic infections, readmissions and death.

  12. Types of infections in hemodialysis unit • Infections due to the process of hemodialysis: • Catheter related Bacteremia…Infective Endocarditis…Metastatic septic emboli • AVF / AVG infections • Dialysate water related infections. • Infectious transmission between patients: • Hepatitis B and C, HIV • MRSA carrier state • Respiratory infections: TB, Influenza, Pneumococcal

  13. Epidemiology of Infections among Hemodialysis Patients • Infections are the 2nd leading cause of death. • Site of infection –57% vascular access –23% wound –15% lung –5% urinary tract USRDS 2005 Annual Data Report • Tokars, Miller, Stein. AJIC 2002;30:288-295

  14. Invasive Methicillin-Resistant S. aureus(MRSA) Infections, 2005 • Incidence of invasive MRSA infections: 45.2 cases per 1,000 dialysis population • 100 times the rate in general population!!! (0.2 –0.4 per 1000) •Invasive MRSA in dialysis • –86% were bloodstream infections (BSIs) • –90% required hospitalization, mortality = 17% CDC. MMWR 2007; 56(09):197-9

  15. Reasons for high infection rates in HD • The process of hemodialysis requires direct vascular access for prolonged periods. • Multiple events occur during dialysis concurrently, so multiple opportunities exist for person-to-person transmission of infectious agents, directly or indirectly. • High risk of contaminated devices, equipment, supplies, environmental surfaces, or hands of personnel. • Immunosuppressed. • Require frequent hospitalizations and surgery, which increases their opportunities for exposure to nosocomial infections.

  16. Vascular Access related InfectionsRisk Factors • Type of access – Catheter >> – AV graft > – AV fistula •Lower extremity access •Recent access surgery •Trauma, hematoma, dermatitis, scratching • Poor hygiene • Poor needle insertion technique • Older age • Diabetes • Iron overload • Others

  17. Rate of Access-Related Bloodstream Infection by Vascular Access Type

  18. CDC Collaborative • In April 2009, the US Centers for Disease Control and Prevention (CDC) announced plans for a collaborative project to prevent BSIs in HD patients. CDC Dialysis BSI Prevention Collaborative Project (2009)

  19. CDC Collaborative to BSI Prevention in Dialysis Units (Core Interventions for Dialysis Bloodstream Infection (BSI) Prevention)

  20. CDC Collaborative – Core Interventions • Surveillance and feedback:Conduct monthly surveillance for BSIs and other dialysis events. Calculate your facility rates and compare to rates in other facilities. Actively share results with front line staff. • Hand hygiene observations: Perform direct observations of hand hygiene monthly and share results with clinical staff. • Catheter/Access care observations: Perform observations of vascular access care and catheter accessing quarterly. Assess staff adherence to aseptic technique when connecting and disconnecting catheters and during dressing changes. Share results with clinical staff.

  21. CDC Collaborative - Core Interventions 4. Chlorhexidinefor skin antisepsis: Use an alcohol-based chlorhexidine (>0.5%) solution as the first line skin antiseptic agent for central line insertion and during dressing changes. 5. Catheter hub disinfection: “Scrub the hubs!” with an appropriate antiseptic after cap is removed and before accessing. Perform every time catheter is accessed or disconnected. 6. Antimicrobial ointment: Apply antibiotic ointment or povidone-iodine ointment to catheter exit sites during each dressing change.

  22. CDC Collaborative - Core Interventions 7. Staff education and competency: Training on infection control topics, including access care and aseptic technique. Competency evaluation for skills such as catheter care and accessing every 6 months. 8. Patient education/engagement. 9. Catheter reduction efforts.

  23. Was the CDC Collaborative Effective??

  24. Blood Stream Infections Preventive Collaborative, AJKD 2013

  25. Blood Stream Infections Preventive Collaborative, AJKD 2013

  26. CDC effort was very effective in reducing BSIs. • A 32% reduction in BSIs and 54% reduction in access related BSIs. • Sustained through the end of evaluation period. • Simple and cost effective interventions. • This initiative helped define that it is achievable to improve and prevent Blood stream infections in dialysis patients through focused efforts.

  27. Need more info?

  28. Current trends in Viral hepatitis in Saudi Arabia

  29. Hepatitis B in Saudi Arabia – A success story! • HBV was once considered hyper-endemic in the Kingdom of Saudi Arabia (KSA). • A 1988 study of Saudi children showed a hepatitis B surface antigen (HBsAg) seroprevalence of approximately 7% and a > 70% prevalence of at least one HBV marker* • This study galvanized the Saudi health officials into action and triggered a successful collaboration between scientists and government agencies. *Al-FalehF. Hepatitis B infection in Saudi Arabia. Ann Saudi Med. 1988;8:474–80.

  30. Hepatitis B in Saudi Arabia – A success story! • A mass vaccination program against HBV was launched in 1989. • The Saudi government initiated a program in 1990 aimed at vaccinating all Saudi children at school entry. • Mandatory vaccination of healthcare workers and hemodialysis patients were also introduced around 1988. • Pre-emptive strategy started: All new born children born after October 01, 1989 be vaccinated against HBV regardless of the mother's HBV status within the country.

  31. Hepatitis B in Saudi Arabia – A success story! Prevalence of HBsAg among the Saudi population documented before and after introducing a nation-wide HBV vaccination program, over an 18-year period. Saudi J Gastro Dec,2012

  32. Is the success story complete?? • The success of low HBV infection rates is only in the younger Saudi populations. (age < 25) • An estimate of HBsAg+prevalence among Saudis greater than 40 years of age falls in the 3-6% range based on data from community-based studies in the late 80s.  • In 2007, MOH ranked viral hepatitis as the second most common viral disease after chickenpox, with almost 9000 new cases diagnosed in that year (52% HBV, 32% HCV, and 16% HAV). • Saudi Arabia: Saudi Arabia Ministry of Health; Ministry of Health of Saudi Arabia (MOH). A review of health situation. The Annual Health Statistics Book, 2007

  33. Hepatitis B Virus Infection in ESRD • Leads to acute / chronic hepatitis, cirrhosis, hepatocellular carcinoma • Distinctly problematic in dialysis patients who are transplant candidates: • Life threatening complications in de novo flares post transplant. • Can occur in any HbsAg + patient at any time post transplant including those who have been very asymtomatic during dialysis.

  34. Hepatitis B in Dialysis • HBV is easily transmitted by percutaneous exposure. • All HBsAg-positive persons are infectious, but those who are also positive for HBeAgcirculate HBV in high titers and are highly infectious. • HBV at low titers of 10²-³virions/mL can be present on environmental surfaces in the absence of any visible blood and still result in transmission.

  35. Hepatitis B in Dialysis • HBV is relatively stable and remains viable for at least 7 days on environmental surfaces at room temperature. • HBsAg has been detected on clamps, scissors, dialysis machine control knobs, and even doorknobs. • Dialysis staff members can readily transfer virus to patients from contaminated surfaces by their hands or gloves or through use of contaminated equipment and supplies

  36. Cross Contamination during dialysis was the major route for spread of HBV • Environmentalsurfaces, supplies (e.g., hemostats,clamps), or equipment that were not routinely disinfected after each use. • Multiple dosemedication vials and IV solutions that were not used exclusively for one pt. • Injectionsthat were prepared in areas adjacent to areas where blood samples were handled • Staffmembers who simultaneously cared for both HBV-infected and susceptible patients

  37. INDEPENDENT RISK FACTORS FOR HBV INFECTION IN DIALYSIS UNITS (DOPPS Data) • Presence of HBsAg positive patients within the same dialysis unit • Non segregation with dedicated hemodialysis machines for HBsAg positive patients • A lower than 50 percent prevalence rate of hepatitis B vaccination among dialysis patients in the same unit. • Absence of a protocol for HBV infected patients. • Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63(6):2222.

  38. Prevention of Hepatitis B in HD unit • Segregation is the key: • Dedicated rooms • Dedicated machines and equipment. • Separate staff • Universal contact precautions • Staff members caring for HBsAg+ pts should not care for HBV-susceptible pts at the same time • Banfrom dialyzer reuse programs i.e. Only single use dialyzers.

  39. Prevention of Hepatitis B in HD unit • Ensure full compliance of Hepatitis B vaccinations • Make sure your unit has an updated standard protocol for care of all HBV patients. • Regular screening of HBsAg status in non-immune individuals • Antiviral treatment of HBV-infection may also reduce the risk of other hemodialysis patients in the same center.

  40. HCV in HD Units worldwide • Prevalence using 3rd generation EIA assay for HCV worldwide shows a wide range from 5.5% to 72%. • DOPPS data of 308 HD facilities in 3 continents reported a mean prevalence of 13.5%.

  41. HCV in Saudi Arabian HD Units • Saudi Data: • Prevalence is variable between 15% and 80%. This prevalence remained at almost 50% in mid 2005 • The annual rate of HCV seroconversion is 7% to 9%. (Hepatitis C in dialysis units: the Saudi experience. HD Intnl 2007 Karkar A.) • However, SCOT 2012 numbers report a decline from 69% in 1996 to 19% as of 2012

  42. HCV Transmission in HD • Transmission of HCV is primarily via percutaneous exposure to infected blood. • HCV can remain viable in the environment for at least 16 hours. • Blood transfusions in 1980-1990s undoubtedly caused many cases of HCV in dialysis units. • Newer data suggest that nosocomial transmissionis the major reason contributing to the high prevalence. • The occurrence of nosocomial transmission has been confirmed by phylogenetic analysis in many studies.

  43. Risk Factors for HCV Infections in ESRD • Number of blood transfusions • Years on dialysis • Mode of dialysis • Prevalence of HCV in dialysis unit • Other factors: • Previous organ transplant • IV drug abuse • Male sex

  44. Unresolved issues in HCV • Debate continues on whether transmission of HCV in HD units may be affected by: • Routine testing for anti-HCV antibodies, • Patient isolation, • Use of dedicated machines, • Ban on dialyzer reuse.

  45. Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients • MMWR Recomm Rep. 2001;50(RR-5):1 • CDC doesnot recommend dedicated machines, patient isolation, or a ban on reuse in HD patients with HCV infection. • However, strict adherence to "universal precautions," careful attention to hygiene, and strict sterilization of dialysis machines is recommended.

  46. The most likely cause of HCV transmission between patients treated in the same dialysis unit is cross-contamination from supplies and surfaces (including gloves) as a result of failure to follow infection-control procedures within the unit. VOLUME 73 | SUPPLEMENT 109 | APRIL 2008

More Related